meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - colorectal cancer (mCRC)
mCRC - (neo)adjuvant (NA)
mCRC - 1st line (L1)
2
mCRC - 2nd line (L2)
3
endometrial cancer
10
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus cometinib
Immune checkpoint association
durvalumab plus tremelimumab
versus all
vs non active control
vs BSC
vs VEGF(R) inhibitor
vs regorafenib
All patients
Age < 65y (younger)
Age > 65y
BRAF mutant
BRAF wild type
dMMR
ECOG 0
ECOG 1
Gender, female
Gender, male
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
AE (any grade)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
DCR
mCRC - 2nd line (L2)
metastatic/advanced - colorectal cancer (mCRC)
mCRC - 2nd line (L2)
versus BSC
durvalumab plus tremelimumab vs. BSC
1
certainty unassessable
+316%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open